Last reviewed · How we verify
mRNA-1345
mRNA-1345 is an mRNA-based vaccine designed to prevent COVID-19 infection by inducing an immune response against the SARS-CoV-2 virus.
mRNA-1345 is an mRNA-based vaccine designed to prevent COVID-19 infection by inducing an immune response against the SARS-CoV-2 virus. Used for Prevention of COVID-19 disease.
At a glance
| Generic name | mRNA-1345 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by encoding for a piece of the SARS-CoV-2 spike protein, which is then produced by the host cells and recognized by the immune system as foreign, triggering an immune response. This immune response helps to prevent future infections by providing immunity against the SARS-CoV-2 virus.
Approved indications
- Prevention of COVID-19 disease
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers (PHASE2)
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age (PHASE3)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months (PHASE1)
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age (PHASE2, PHASE3)
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1345 CI brief — competitive landscape report
- mRNA-1345 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI